person
Oscar J.
- Country
- Spain
- Department
- Oncology
Research Overview
assignment
4
Clinical Trials ·
- Evaluation of Brigatinib Efficacy in ALK-Positive Non-Small Cell Lung Cancer via Liquid Biopsy: An Exploratory Study
- Phase 1/2a Open-Label Study of BMS-986507 in Combination with Pembrolizumab and Osimertinib Mesylate in Advanced Solid Tumors
- A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
21
Sites with multiple studies
Has run more than one trial at 21 of 141 partner sites.
Specializations
Lung Cancer Expertise
This investigator specializes in treating various forms of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with particular emphasis on advanced and metastatic disease states.
- Stage II-IIIB NSCLC treatment approaches
- Extensive stage SCLC management
- Limited stage SCLC interventions
Molecular Targeting
The investigator focuses on precision medicine approaches targeting specific genetic mutations in lung cancer, including EGFR mutations, HER2 alterations, and KRAS G12C mutations.
- EGFR exon mutations
- MET amplifications
- ALK-positive NSCLC
Treatment Modalities
Expertise in evaluating novel therapeutic approaches combining immunotherapy, targeted therapies, and chemotherapy for lung cancer treatment.
- Neoadjuvant therapy
- Combination immunotherapy
- Monoclonal antibody treatments
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.